BioNovelus inc
Balance Sheet
As of September 30, 2015

BioNovelus, Inc.
Balance Sheet
For the Year Ended December 31

	BioNovelus Inc. 2015	Firstin Wireless 2014
ASSETS		
Current Assets		
Checking/Savings		
Cash	134	5,106
Total Checking/Savings	134	5,106
Account Receivable	0	0
Total Current Assets	134	5,106
Fixed Assets		
Accumulated Amortization	(35,031)	0
Intellectual Property	700,620	0
Total Fixed Assets	665,589	0
TOTAL ASSETS	**665,723**	**5,106**
LIABILITIES & EQUITY		
Liabilities		
Current Liabilities		
Accounts Payable		
Accounts Payable Ekobo	9,300	0
Total Accounts Payable	9,300	0
Other Current Liabilities		
Accrued Interest	29,868	0
Accrued Interest - Officers	7,582	0
Loan from Ekobo	330	0
Loan from Ben & Karen Kim	0	(16,250)
Loan from James Termine	73,676	34,975
Total Other Current Liabilities	111,456	18,725
Notes Payable to Officers	240,816	0
Notes Payable to Related Parties	100,000	0
Notes Payable Unrelated Parties		
Note Payable - James P Perrine	1,000	0
Note Payable #1 -	2,500	0
Note Payable #10 -	25,000	0
Note Payable #11 -	12,500	0
Note Payable #14 -	50,000	0
Note Payable #2 -	15,060	0
Note Payable #3 -	7,000	0
Note Payable #4 -	25,500	0
Note Payable #5 -	5,785	0
Note Payable #6 -	10,000	0
Note Payable #7 -	25,000	0
Note Payable #8 -	1,500	0
Note Payable #9 -	25,000	0
Total Notes Payable Unrelated Parties	205,845	0
Total Current Liabilities	667,417	18,725
Total Liabilities	667,417	18,725
Equity		
Common Stock	83,268	0
Paid in Capital	666,381	19,358
Preferred Stock	10,000	0
Retained Earnings	(638,684)	(15)
Net Income	(122,658)	(32,963)
Total Equity	(1,694)	(13,619)
TOTAL LIABILITIES & EQUITY	**665,723**	**5,106**

BioNovelus, Inc.
Footnotes to Financial Statements
For the Year Ending December 31, 2015

NOTE 1 -ORGANIZATION

BioNovelus Inc. (BioNovelus) is an Arizona based biotech company that aims to develop a portfolio of green solutions for many applications. The solutions address major global challenges: food and water safety and supply.

BioNovelus was founded in September 2010 to answer critical environmental problems by replacing harmful chemicals with eco-friendly and profitable technology to aid our planet.

NOTE 2 -SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation: Information and note disclosures in these financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").

Cash and Cash Equivalents: Cash and cash equivalents consists of cash on hand, undeposited funds, amounts on deposit with financial institutions and certificates of deposit available for withdrawal.

Intellectual Property - All research and development costs are normally expensed as incurred. Since there was a reverse acquisition/merger in May 2015 with Firstin Wireless Technology, Inc. , those rules change per GAAP. Stock is being issued for the product, the cost of the stock (which is $0.01 per share) becomes the fair market value based on the number of shares. To calculate the fair market value, the number of shares was multiplied by $0.01 to come up with the fair market value.

Income Taxes: The company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing tax assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled.

Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

NOTE 3 - Concentration of Risk

BioNovelus maintains cash and cash equivalents at various financial institutions. Deposits not to exceed $250,000 at each financial institution are insured by the Federal Deposit Insurance Corporation. As of December 31, 2015, BioNovelus's bank balances did not exceed this limit.

NOTE 4 - Related Parties Debt

BioNovelus has outstanding notes payable to its President for $240,816 and others for $100,000 as of December 31, 2015. There are several unsecured notes but the terms are consistent as follows:

Due on demand with 3% interest

In addition, there are loans payable of $74,006 to officers and other related parties. These loans are not secured and do not accrue interest. Principal is due on demand.

NOTE 5 - Notes Payable

BioNovelus has outstanding notes payable of $205,845 as of December 31, 2015. The terms of the notes are as follows:

Unsecured demand notes at 3% interest per annum	$51,000
Convertible notes 1t 11% interest with various due dates in 2016	$154,845

BioNovelus, Inc.
Income Statement
For the Year Ending December 31,

	BioNovelus, Inc. 2015	Firstin Wireless 2014
Ordinary Income/Expense		
Expense		
Accounting	2,500	908
Advertising and Promotion	1,053	50
Amortization Expense	35,031	-
Auto and Truck Expenses	498	-
Bank Service Charges	221	235
Car rental	463	-
Cleaning	33	-
Computer and Internet Expenses	359	-
Interest Expense	37,450	-
Lab Testing	4,250	-
Licenses & Permits	895	-
Mail Service	451	-
Meals and Entertainment	1,262	-
N/P Ekobo	1,025	-
Office Supplies	490	-
Parking	12	-
Printing and Reproduction	10	-
Professional Fees		
Grant Fees	750	1,000
Legal Fees	275	3,760
Professional Fees - Other	16,651	27,010
Total Professional Fees	17,676	31,770
Research & Development	1,500	-
SCC & OTC Filing	12,683	-
Stock Management	1,545	-
Susbscription	30	-
Taxes	64	-
Travel	2,392	-
Travel Expense	767	-
Total Expense	122,658	32,963
Net Ordinary Income	(122,658)	(32,963)
Net Income	**(122,658)**	**(32,963)**

BioNovelus, Inc.
Statement of Cash Flows
For the Year Ending December 31,

	BioNovelus, Inc. 2015	Firstin Wireless 2014
OPERATING ACTIVITIES		
Net Income	-122,658	-32,963
Adjustments to reconcile Net Income		
to net cash provided by operations:		
Accounts Payable Ekobo	9,300	0
Accrued Interest	29,868	0
Accrued Interest - Officers	7,582	0
Loan from Ekobo	330	0
Loan Repayment from Ben & Karen Kim	16,250	-16,250
Loan from James Termine	38,701	34,975
Account Receivable		0
Net cash provided by Operating Activities	-20,627	-14,238
INVESTING ACTIVITIES		
Accumulated Amortization	35,031	0
Intellectual Property	-700,620	0
Net cash provided by Investing Activities	-665,589	0
FINANCING ACTIVITIES		
Notes Payable to Officers:Note Payable #13 -J Ekobo	130,000	0
Notes Payable to Officers:Note Payable #15 - JN Ekobo	7,500	0
Notes Payable to Officers:Note Payable #16 - JN Ekobo	7,500	0
Notes Payable to Officers:Note Payable #17 - JN Ekobo	4,700	0
Notes Payable to Officers:Note Payable #18 - JN Ekobo	55,731	0
Notes Payable to Officers:Note Payable #19 - JN Ekobo	4,500	0
Notes Payable to Officers:Note Payable #20 - JN Ekobo	5,030	0
Notes Payable to Officers:Note Payable #21 - JN Ekobo	16,055	0
Notes Payable to Officers:Note Payable #22 - JN Ekobo	5,500	0
Notes Payable to Officers:Note Payable #24 - JN Ekobo	3,000	0
Notes Payable to Officers:Note Payable #25 - Jean Ekobo	900	0
Notes Payable to Officers:Note Payable #26 - Jean Ekobo	400	0
Notes Payable toRelated Parties:Note Payable #12 - Terra G	100,000	0
Notes Payable Unrelated Parties:Note Payable - James P P	1,000	0
Notes Payable Unrelated Parties:Note Payable #1 -	2,500	0
Notes Payable Unrelated Parties:Note Payable #10 -	25,000	0
Notes Payable Unrelated Parties:Note Payable #11 -	12,500	0
Notes Payable Unrelated Parties:Note Payable #14 -	50,000	0
Notes Payable Unrelated Parties:Note Payable #2 -	15,060	0
Notes Payable Unrelated Parties:Note Payable #3 -	7,000	0
Notes Payable Unrelated Parties:Note Payable #4 -	25,500	0
Notes Payable Unrelated Parties:Note Payable #5 -	5,785	0
Notes Payable Unrelated Parties:Note Payable #6 -	10,000	0
Notes Payable Unrelated Parties:Note Payable #7 -	25,000	0
Notes Payable Unrelated Parties:Note Payable #8 -	1,500	0
Notes Payable Unrelated Parties:Note Payable #9 -	25,000	0
Common Stock	83,268	0
Equity from Charles Kim	-8,560	8,560
Equity from Ekobo	-10,798	10,798
Paid in Capital	666,381	0
Preferred Stock	10,000	0
Retained Earnings	-605,707	0
Net cash provided by Financing Activities	681,245	19,358
Net cash increase for period	-4,971	5,120
Cash at beginning of period	5,106	-15
Cash at end of period	**134**	**5,106**

BioNovelus, Inc.
Statement of StockHolders Equity

	Preferred Stock		Common Stock		Additional	Retained Earnings	
	# of Shares	Amount	# of Shares	Amount	Paid in Capital	Accumulated deficit	Total
Balance, December 31, 2014	-	-	-	-	19,358	(638,684)	(619,326)
Return to Treasury			-	-	(19,358)		
New Shares	10,000,000	10,000					
Issued From Treasury - Acquisition			70,062,003	70,062	630,558		
Sale of Stocks			5,386	5			
Note Payables Converted to Stocks			13,200,580	13,201	27,225		
Loan Paid in Conjunction with Paid in Capital					8,598		
Net Loss at December 31, 2015						(122,658)	
Balance, December 31, 2015	**10,000,000**	**10,000**	**83,267,969**	**83,268**	**666,381**	**(761,343)**	**(1,694)**
